OBJECTIVE: It has been suggested that early onset preeclampsia (EPE) and late onset preeclampsia (LPE) represent two different and distinct entities. LPE is more common, and usually less severe than EPE. Yet, while these terms are widely used, there is no clear definition of the gestational age cut-off between early and late preeclampsia, and various studies named different thresholds between 32 and 36 weeks. We aimed to establish this gestational age cut-off using placental pathology, mainly maternal vascular malperfusion lesions (MVM's), which are the hallmark of placental findings in preeclampsia. STUDY DESIGN: This was a retrospective analysis of all women with singleton gestations, at or beyond 24 weeks of gestation, diagnosed with preeclampsia, who delivered between 2001 and 2015 at a single, tertiary referral center. Placental abnormalities were classified into lesions related to maternal vascular malperfusion, fetal vascular malperfusion, lesions associated with hemorrhage and chronic inflammation. Placental findings were compared by gestational age at delivery. RESULTS: A total of 430 women with singleton gestation and preeclampsia were eligible for analysis. Out of all of the placental pathology parameters examined, MVM's emerged as potential candidate to define the gestational age cut-off between LPE and EPE, as the prevalence of these findings decreased significantly at 35 0/7 weeks of gestation ( Figure) . The prevalence of one or more MVM's was significantly higher < 35 0/7 weeks of gestation (93.2% vs. 47.3%, p<0.001) (Table) . Comparing the prevalence of 2 and 3 different types of MVM's (as more sensitive markers of placental ischemia), before and after 35 0/7 weeks of gestation, the same pattern was even more pronounced, (68.2% vs. 13.3%, p<0.001 for 2 MVM's and 33.2% vs. 3.3%, p<0.001 for 3 MVM's).
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In a multivariable regression model, maternal age and nulliparity were not found to influence this association. In a sub-analysis of only appropriately grown neonates (birthweight>10% percentile, n¼324), 35 0/7 gestational weeks remained a valid threshold (91.6% vs. 37.2% for 1 MVM's, 61.6% vs. 6.6% for 2 MVM's and 28.1% vs. 1.7% for 3 MVM's, p<0.001 for all) (Table) CONCLUSION: Based on the differences in the prevalence of MVM's in placental pathology specimens, the gestational age cut-off between early and late preeclampsia is 35 0/7 weeks. OBJECTIVE: Preeclampsia (PE) occurs in 3%e8% of all pregnancies and is a leading cause of maternal morbidity and mortality. Currently the only successful treatment for PE is delivery of the baby and placenta. Metformin, a biguanide medication, is used as treatment for type 2 diabetes and an acceptable oral agent for treatment of gestational diabetes. It has several mechanisms of action including targeting inflammatory, oxidative stress and vascular dysfunction pathways. Our hypothesis was that metformin reduces inflammation using an established obese mouse model of PE. STUDY DESIGN: Female CD-1 mice were fed high fat diet for 3 months, and then mated with CD-1 male. On day 1 of gestation, mice were randomly assigned to receive metformin (300 mg/kg, MET group) in drinking water or just plain drinking water (CTR group). On day 8 of gestation mice were injected with either adenovirus vector carrying sFl1 (AdsFlt1, 109 PFU/100 mL) or mFc (AdmFc, 109 PFU/100 mL as a virus control). Mice were sacrificed on day 18 of gestation and blood was collected. The levels of IL-6, Leptin, Insulin, Plasminogen activator inhibitor -1 (PAI-1), MCP-1, and Resistin were determined using LuminexÒ bead array. Data were analyzed using Student t-test or Mann-Whitney test as appropriate (significance was defined as p<0.05).
RESULTS:
Mice that received metformin had lower circulating levels of IL-6 and MCP-1 when compared to control mice (P¼0.02 and P¼0.04, respectively, Figure) . There was no difference in the adipokines, leptin or resistin and no difference in circulating insulin or PAI-1 levels. OBJECTIVE: Endothelin-converting enzyme 1 (ECE-1) is a key regulatory enzyme in the proteolytic processing of Endothelin-1 (ET-1), a potent vasoactive peptide. In most vascular beds, ECE-1 localizes to endothelial cells, but has not been extensively studied in the human placenta. We sought to evaluate the expression and cellular localization of ECE-1 in normal and preeclamptic placentas. STUDY DESIGN: Placentas from normal (n¼6) and preeclamptic (n¼6) women, matched for gestational age, were collected and serially sectioned for immunofluorescence (IF) studies to localize ECE-1 expression. Cell type specific markers were used to identify the following cell types: endothelial, trophoblast, macrophage, smooth muscle and fibroblast cells. The samples were stained with antibodies for ECE-1 and tissue markers and counterstained with DAPI. Negative controls were stained with secondary antibodies and DAPI. Quantitative analysis of ECE-1 within placenta samples was performed by western blot and ELISA. RESULTS: Immunofluorescence studies confirmed ECE-1 expression within the stroma and villous spaces of intermediate and stem villi of human placentas. Localization of ECE-1 occurred occasionally with endothelial cells but not with the other cell types evaluated (Figure 1 ). IF studies suggested less ECE-1 expression in preeclamptic placentas. Western blot and ELISA showed significantly less ECE-1 in preeclamptic compared with normal placentas (Figure 2) . CONCLUSION: ECE-1 is expressed in the villous spaces of the human placenta. There is significantly less ECE-1 expression in preeclamptic versus normal placentas. ECE-1 likely plays an important role in vascular homeostasis in the placenta and may be protective against disorders of vascular dysfunction, such as preeclampsia. The lack of colocalization of ECE-1 suggests a secreted form of the enzyme, however further study is needed to confirm this.
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